Ritodrine hydrochloride

A betamimetic agent for use in preterm labor: II. evidence of efficacy

Irwin R. Merkatz, John B. Peter, Tom P. Barden

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

In a multicenter series of randomized prospective doubleblind controlled studies, ritodrine hydrochloride was compared with either ethanol or placebo in treatment of idiopathic preterm labor. When compared with controls, there was, among offspring of ritodrine-treated mothers, a significantly reduced incidence of neonatal death and respiratory distress syndrome (P<.05 in both comparisons) and a significantly higher proportion of infants achieving 36 weeks' gestation (P<.05) or birth weight greater than 2500 g (P<.05). There was also a significant improvement in gestational age at delivery (P<.05) and in the number of days gained in utero (P<.001) among ritodrine-treated patients as compared with controls. These results, coupled with a finding of generally acceptable side effects, have contributed to ritodrine's becoming the first drug approved for the treatment of preterm labor in the United States.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalObstetrics and Gynecology
Volume56
Issue number1
StatePublished - 1980
Externally publishedYes

Fingerprint

Ritodrine
Adrenergic beta-Agonists
Premature Obstetric Labor
Newborn Respiratory Distress Syndrome
Birth Weight
Gestational Age
Ethanol
Placebos
Mothers
Pregnancy
Incidence
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Ritodrine hydrochloride : A betamimetic agent for use in preterm labor: II. evidence of efficacy. / Merkatz, Irwin R.; Peter, John B.; Barden, Tom P.

In: Obstetrics and Gynecology, Vol. 56, No. 1, 1980, p. 7-12.

Research output: Contribution to journalArticle

@article{33b5ac0e72ef49d087a8d49563e372cf,
title = "Ritodrine hydrochloride: A betamimetic agent for use in preterm labor: II. evidence of efficacy",
abstract = "In a multicenter series of randomized prospective doubleblind controlled studies, ritodrine hydrochloride was compared with either ethanol or placebo in treatment of idiopathic preterm labor. When compared with controls, there was, among offspring of ritodrine-treated mothers, a significantly reduced incidence of neonatal death and respiratory distress syndrome (P<.05 in both comparisons) and a significantly higher proportion of infants achieving 36 weeks' gestation (P<.05) or birth weight greater than 2500 g (P<.05). There was also a significant improvement in gestational age at delivery (P<.05) and in the number of days gained in utero (P<.001) among ritodrine-treated patients as compared with controls. These results, coupled with a finding of generally acceptable side effects, have contributed to ritodrine's becoming the first drug approved for the treatment of preterm labor in the United States.",
author = "Merkatz, {Irwin R.} and Peter, {John B.} and Barden, {Tom P.}",
year = "1980",
language = "English (US)",
volume = "56",
pages = "7--12",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Ritodrine hydrochloride

T2 - A betamimetic agent for use in preterm labor: II. evidence of efficacy

AU - Merkatz, Irwin R.

AU - Peter, John B.

AU - Barden, Tom P.

PY - 1980

Y1 - 1980

N2 - In a multicenter series of randomized prospective doubleblind controlled studies, ritodrine hydrochloride was compared with either ethanol or placebo in treatment of idiopathic preterm labor. When compared with controls, there was, among offspring of ritodrine-treated mothers, a significantly reduced incidence of neonatal death and respiratory distress syndrome (P<.05 in both comparisons) and a significantly higher proportion of infants achieving 36 weeks' gestation (P<.05) or birth weight greater than 2500 g (P<.05). There was also a significant improvement in gestational age at delivery (P<.05) and in the number of days gained in utero (P<.001) among ritodrine-treated patients as compared with controls. These results, coupled with a finding of generally acceptable side effects, have contributed to ritodrine's becoming the first drug approved for the treatment of preterm labor in the United States.

AB - In a multicenter series of randomized prospective doubleblind controlled studies, ritodrine hydrochloride was compared with either ethanol or placebo in treatment of idiopathic preterm labor. When compared with controls, there was, among offspring of ritodrine-treated mothers, a significantly reduced incidence of neonatal death and respiratory distress syndrome (P<.05 in both comparisons) and a significantly higher proportion of infants achieving 36 weeks' gestation (P<.05) or birth weight greater than 2500 g (P<.05). There was also a significant improvement in gestational age at delivery (P<.05) and in the number of days gained in utero (P<.001) among ritodrine-treated patients as compared with controls. These results, coupled with a finding of generally acceptable side effects, have contributed to ritodrine's becoming the first drug approved for the treatment of preterm labor in the United States.

UR - http://www.scopus.com/inward/record.url?scp=0018963719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018963719&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 7

EP - 12

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -